Antigen epitope of African swine fever virus pH108R protein, monoclonal antibody based on antigen epitope and related application

By identifying and preparing the 40-50 antigen epitope of the pH108R protein of the African swine fever virus, a specific monoclonal antibody was developed, which solved the shortcomings in the study of the virus, provided effective tools for detection and research, and achieved the goal of The stability and efficient recognition of pH108R protein.

CN118955651AInactive Publication Date: 2024-11-15ZHENGZHOU UNIV +1

Patent Information

Application Number
CN202411234228.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art studies on the pH108R protein of the African swine fever virus are rarely studied, and the lack of relevant monoclonal antibodies and antigen epitopes limits the in-depth study of the biological function of the virus and vaccine development.

Method used

By identifying and preparing the 40-50 antigen epitope of the pH108R protein of the African swine fever virus, monoclonal antibodies that specifically recognize the region were developed, and the protein was expressed using the E. coli expression system, and antibodies were prepared by immunological methods. Tools for detection and research.

Benefits of technology

The specific recognition and binding of the ASF virus pH108R protein has been achieved, providing valuable tools for research and vaccine development, with stability and efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955651A_ABST
    Figure CN118955651A_ABST
Patent Text Reader

Abstract

The invention discloses an antigen epitope of African swine fever virus pH108R protein, a monoclonal antibody based on the antigen epitope and related application, and belongs to the technical field of genetic engineering. PH108R recombinant protein is used as immunogen to immunize mice, and the monoclonal antibody generated by a cell strain is obtained by utilizing cell fusion and subcloning technologies; the monoclonal antibody can specifically recognize and be combined with a 40SNIHIPYQWLA50 sequence region on a pH108R (Potential of Hydrogen 108R) protein. The African swine fever pH108R epitope peptide is obtained through identification, the monoclonal antibody specifically combined with the African swine fever pH108R protein is prepared, and a foundation is laid for preparing an African swine fever detection kit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of genetic engineering technology, and in particular relates to an antigenic epitope of the pH108R protein of an African swine fever virus, a monoclonal antibody based thereon, and related applications. Background Art

[0002] African swine fever (ASF) is a deadly and highly contagious pig disease caused by the African swine fever virus (ASFV). The mortality rate of infected pigs can be as high as 100%, posing a major threat to the global pig industry, food security and rural development. Currently, the disease is listed as a notifiable disease by the World Organization for Animal Health (WOAH).

[0003] African swine fever virus is the only member of the Asfarviridae family. It is an insect-borne DNA virus of the double-stranded Nucleocytoplasmic Large DNA Viruses (NCLDV) family and is the pathogen of African swine fever. Depending on the virus strain, the size of the DNA is between 170 and 190 kbp, which can encode more than 150 open reading frames (ORFs), encoding 150 to 200 viral proteins, including 68 structural proteins and more than 100 non-structural proteins. Based on the nucleotide sequence of the 478 bp variable region at the C-terminus of the ASFVp72 gene, ASFV can be divided into 24 genotypes. ASFV particles are icosahedral multilayer structures with a diameter of 200 nm, including envelope, capsid, inner capsule membrane, nucleocapsid and inner core from the outside to the inside. The pH108R protein is located in the inner capsule of the virus particle, and its N-terminus contains a transmembrane domain. The pH108R protein is expressed in the late stage of ASFV infection. This protein can induce an immune response and plays an important role in the replication and morphogenesis of the virus. Studies have found that the H108R gene is a new viral virulence determinant cluster. Deleting it from the ASFV-G genome can significantly reduce the virulence of the virus in domestic pigs. In addition, animals that survived the inoculation of the recombinant virus ASFV-G-ΔH108R containing the H108R gene deletion can resist the attack of the highly toxic parental virus. Although ASFV-G-ΔH108R has residual toxicity, it can provide protection even at low doses, suggesting that it has the potential to serve as an additional gene deletion to increase the safety of existing vaccine candidates.

[0004] At present, there are few studies on ASFV pH108R protein. Recombinant expression of pH108R protein, preparation of its specific monoclonal antibody, and screening and identification of pH108R protein using scanning peptide technology are of great significance for in-depth study of the biological function of pH108R protein. Summary of the invention

[0005] The present invention aims to provide an antigenic epitope of the pH108R protein of African swine fever virus and a monoclonal antibody based thereon and related applications, wherein the monoclonal antibody can specifically recognize the antigenic epitope of the pH108R protein of African swine fever virus. 40 SNIHIPYQWLA 50 Sequence region, which is the first reported B-cell epitope of pH108R protein, lays a foundation for the research and development of related technologies for existing technologies.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides an antigenic epitope of the African swine fever virus pH108R protein. The antigenic epitope is located at positions 40 to 50 of the African swine fever virus pH108R protein. The amino acid sequence of the antigenic epitope is shown in SEQ ID No.1.

[0008] The present invention also provides the use of an antigenic epitope of the pH108R protein of the African swine fever virus in preparing a monoclonal antibody against the pH108R protein of the African swine fever virus, and the antigenic epitope is as shown above.

[0009] The present invention also provides a monoclonal antibody against the pH108R protein of African swine fever virus, and the monoclonal antibody can specifically bind to the above-mentioned antigen epitope.

[0010] In the present invention, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No.2, and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID No.3.

[0011] The present invention also provides a nucleic acid encoding a monoclonal antibody against the pH108R protein of African swine fever virus, wherein the nucleic acid encoding the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No.4, and the nucleic acid encoding the light chain variable region of the monoclonal antibody is shown as SEQ ID No.5.

[0012] The present invention also provides an expression vector, which comprises the above-mentioned nucleic acid.

[0013] The present invention also provides a host cell, which comprises the above expression vector.

[0014] The present invention also provides a kit for detecting African swine fever virus pH108R protein, the kit comprising the above-mentioned monoclonal antibody against African swine fever virus pH108R protein and / or the above-mentioned nucleic acid and / or the above-mentioned expression vector and / or the above-mentioned host cell.

[0015] The present invention also provides the use of the above-mentioned monoclonal antibody against African swine fever virus pH108R protein and / or the above-mentioned nucleic acid and / or the above-mentioned expression vector and / or the above-mentioned host cell in the preparation of a drug for inhibiting and / or neutralizing African swine fever virus pH108R protein.

[0016] The present invention discloses the following technical effects:

[0017] The monoclonal antibody of the African swine fever virus pH108R protein provided by the present invention is prepared by expressing the pH108R protein using an Escherichia coli expression system, and then using the purified pH108R protein as an immunogen to immunize BALB / c mice by an immunological method. The monoclonal antibody can specifically recognize and bind to the specific linear B cell epitope region at positions 40 to 50 of the African swine fever virus pH108R protein, and has the advantages of strong specificity and good stability, which provides a valuable tool for further studying the biological function of the pH108R protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 PCR results for the pH108R target gene;

[0019] Figure 2 This is the PCR result of the recombinant plasmid pET-32a-pH108R bacterial solution;

[0020] Figure 3 Purification and identification of pH108R recombinant protein; Figure A: SDS-PAGE identification of pH108R recombinant protein purification; M in Figure A: Marker; Figure A 1: pH108R recombinant protein before purification; Figure A 2: pH108R recombinant protein after purification; Figure B: Western Blot identification with anti-His-tag monoclonal antibody; M in Figure B: Marker; Figure B 1: pH108R recombinant protein; Figure C: Western Blot identification with ASFV standard positive pig serum; M in Figure C: Marker; Figure C 1: pH108R recombinant protein;

[0021] Figure 4 This is a graph of mouse polyclonal antibody titers;

[0022] Figure 5 Western Blot identification of hybridoma cell lines;

[0023] Figure 6 To verify the reactivity of hybridoma cell lines with eukaryotic expressed proteins for IFA;

[0024] Figure 7 The expression and identification of truncated proteins; Figure A is SDS-PAGE analysis; Figure B is Western Blot anti-His-tag monoclonal antibody identification; Figure C is SDS-PAGE analysis; Figure D is Western Blot anti-His monoclonal antibody identification; In the above figures, M: Maker; Markers 1 to 3 are: B1, B2, B3 expression bacteria ultrasonic supernatant; Markers 4 to 6 are: B4, B5, B6 expression bacteria ultrasonic supernatant;

[0025] Figure 8 This is the first screening of truncated epitope regions; Figure A is: Indirect ELISA identification results; Figure B is: Dot-Blot identification results

[0026] Fig. 9 This is the second screening of truncated epitope regions; Figure A is: indirect ELISA identification results; Figure B is: Dot-Blot identification results;

[0027] Fig.10 Figure 1 is a diagram of monoclonal antibody ascites purification; Figure A is: SDS-PAGE identification of 1D1 monoclonal antibody purification; Figure B is: SDS-PAGE identification of 4C6 monoclonal antibody purification; In the above figures, M: Marker; Marker 1: before purification; Marker 2: after purification;

[0028] Fig.11 Figure 1 is the titer of the purified monoclonal antibody; Figure A is the titer determination of the 1D1 monoclonal antibody; Figure B is the titer determination of the 4C6 monoclonal antibody;

[0029] Fig.12 Figure 1 is the regression curve of the affinity constant of the purified monoclonal antibody; Figure A is the affinity determination of the 1D1 monoclonal antibody; Figure B is the affinity determination of the 4C6 monoclonal antibody;

[0030] Fig.13 The results of identification of peptide P1 and monoclonal antibody; Figure A: Peptide-ELISA identification results; Figure B: Dot-Blot identification results; NC: PBS;

[0031] Fig.14 The results are the identification of peptides and ASFV standard positive pig serum; Figure A is: Peptide-ELISA identification results; Figure B is: Dot-Blot identification results; NC: PBS. DETAILED DESCRIPTION

[0032] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0033] Example 1

[0034] Selection and preparation of immunogens

[0035] pH108R protein is a structural protein of ASFV, which is expressed in the late stage of ASFV infection. This protein can induce an immune response and plays an important role in the replication and morphogenesis of the virus. The preparation of anti-ASFV pH108R protein monoclonal antibodies and the identification of pH108R protein antigenic epitopes are of great significance for the prevention and detection of the disease. Therefore, the present invention uses pH108R protein as an immunogen. Specifically, the preparation of the immunogen includes the following steps:

[0036] 1. Primer Design

[0037] According to the H108R gene sequence information of the ASFV China / 2018 / AnhuiXCGQ strain published by NCBI (http: / / www.ncbi.nlm.nih.gov), the pH108R gene primers were designed using SnapGene software, the transmembrane region was removed, and the two restriction sites of BamH I and XhoⅠ (underlined parts) were selected to synthesize the ASFV China2018AnhuiXCGQ-pH108R gene. The primer sequences are shown in Table 1:

[0038] Table 1 Primer sequence list

[0039]

[0040] Note: The underlined part is the restriction site

[0041] 2. PCR Amplification of pH108R Gene

[0042] The synthesized pH108R extracellular region gene sequence was used as a template for PCR amplification. The PCR amplification system is as follows:

[0043] Table 2 PCR amplification system

[0044]

[0045] 3. Purification and recovery of PCR products

[0046] After amplification, the product was identified by electrophoresis using 1% nucleic acid gel. Figure 1As shown. Finally, the PCR product with a band close to the target band was selected and purified using a DNA purification and recovery kit. The concentration of the recovered DNA solution was determined using NanoDrop2000c and stored at -20°C for later use.

[0047] 4. Double restriction enzyme digestion of target gene and vector

[0048] (1) The pH108R gene and the pET-32a vector were double-digested, and the digestion reaction system was shown in Table 3 below:

[0049] Table 3 Double enzyme digestion reaction system

[0050]

[0051] (2) After mixing all components, place them in a 37°C thermostat for overnight enzyme digestion.

[0052] 5. Recovery of enzyme digestion products

[0053] Use a gel recovery kit to recover the enzyme cleavage product, aspirate 2 μL of the solution in the centrifuge tube to measure the concentration of the recovered DNA, and store it at -20°C for future use.

[0054] 6. Construction of recombinant plasmid

[0055] (1) Ligation of pH108R gene with pET-32a vector

[0056] Add the following components into the EP tube:

[0057] Table 4 Connection system

[0058]

[0059] After mixing the above solutions in the centrifuge tube, place it in a 16°C connector for overnight connection.

[0060] (2) Conversion

[0061] Pipette 10 μL of the ligation product and add it to 100 μL of DH5α competent cells, add 900 μL of non-resistant LB liquid culture medium, and culture at 37°C, 220 r / min and shaking for 50 min; after the culture is completed, centrifuge the solution in the centrifuge tube at 4000 r / min for 4 min at room temperature, discard the supernatant, and resuspend the bacterial pellet with 100 μL of liquid LB culture medium; evenly spread the above resuspension on the LB solid culture medium containing ampicillin resistance, culture it flat at room temperature for 20 min, and then invert it in a 37°C constant temperature incubator for overnight culture.

[0062] (3) Screening of positive clones by PCR

[0063] Pick a single smooth colony and inoculate it in LB liquid medium containing ampicillin resistance, then culture at 37°C, 220r / min for 6h, and take 1μL of bacterial solution as a template for bacterial solution PCR. Add the following components into the EP tube:

[0064] Table 5 Bacterial liquid PCR reaction system

[0065]

[0066] After mixing the above reaction components, place them in a PCR instrument for PCR amplification. After the bacterial solution PCR is completed, the product is identified using a 1% nucleic acid gel. The results are as follows Figure 2 As shown, there is a single target band at 250 bp, indicating that the recombinant expression vector was successfully constructed. The positive colonies were sent to Universal Biotech for sequencing.

[0067] (4) Obtaining recombinant plasmid

[0068] The positive strains that were successfully sequenced were selected and cultured overnight in liquid LB medium containing ampicillin resistance at 37°C and 220 r / min. The pET-32a-pH108R recombinant plasmid was extracted according to the instructions of the plasmid mini-extraction kit.

[0069] 7. Induced expression and purification of recombinant vector

[0070] In order to obtain the prokaryotic expression of pH108R protein, the constructed recombinant plasmid pET-32a-pH108R was transformed into Escherichia coli BL21 (DE3) competent cells, induced by isopropyl β-D-1-thiogalactopyranoside (IPTG) for 8 hours, and then ultrasonically disrupted and centrifuged at low temperature and high speed to separate the supernatant and precipitate. The supernatant was purified by nickel column affinity chromatography, and the recombinant protein pH108R was obtained after dialysis with phosphate buffer. The purified protein was identified by SDS-PAGE and Western Blot.

[0071] In the Western Blot detection process, the protein sample was subjected to SDS-PAGE electrophoresis, and then the protein was transferred to the PVDF membrane by transfer. After the PVDF membrane was incubated in 5% skim milk at room temperature for 2 hours, the membrane was immersed in a 5% skim milk solution containing the primary antibody and incubated in a constant temperature incubator at 37°C for 1 hour. The secondary antibody used a 5% skim milk solution of commercial HRP-goat anti-pig IgG (1:5000) or HRP-goat anti-mouse IgG (1:5000) at room temperature for 1 hour. Finally, the PVDF was washed and developed with ECL.

[0072] SDS-PAGE results showed that pH108R protein was effectively purified ( Figure 3A). Western blot analysis showed that the purified protein could be detected by His tag antibody ( Figure 3 B) and ASFV positive serum ( Figure 3 C) Identification.

[0073] Example 2

[0074] Preparation of monoclonal antibodies

[0075] 1. Animal immunization

[0076] pH108R protein was used as an immunogen to immunize two BALB / c mice, and the mice were injected subcutaneously at multiple points on their backs. For the first immunization, Freund's complete adjuvant was mixed with an equal volume of protein for emulsification, and the immunization dose for each mouse was 25 μg. One week after the first immunization, a booster immunization was performed. Freund's incomplete adjuvant was mixed with protein for emulsification and injected subcutaneously into the mice. The third immunization was performed one week after the second immunization. Blood was collected from the tail of the mice one week after the third immunization, and the serum was separated and the titer was tested. Unimmunized mice were used as negative controls.

[0077] 2. Indirect ELISA to determine the titer of mouse serum

[0078] The titer of the polyclonal antibody serum of mice was measured one week after the three immunizations. Figure 4 As shown, the titer of mouse No. 1 is 1:1.024×10 5 , the titer of mouse No. 2 reached 1:2.048×10 5 Mice with high titers were selected for intraperitoneal booster immunization. The protein was directly injected into the mice through the peritoneal cavity, and the cells fused after 3 to 5 days.

[0079] 3. Preparation of Feeder Cells

[0080] One day before cell fusion, a Kunming mouse in good growth condition was selected to prepare feeder layer cells. The specific steps are as follows:

[0081] (1) The mice were killed and immersed in 75% alcohol. After 5 minutes, the limbs of the mice were fixed on a foam board with the abdomen facing upward.

[0082] (2) Transfer the mouse to a clean bench and cut the mouse's abdominal epidermis with sterile scissors.

[0083] (3) Use sterile forceps to pick up the mouse peritoneum, draw up 20 mL of HAT culture medium with a syringe, pierce the peritoneum and slowly inject the culture medium into the mouse abdominal cavity, gently massage the mouse abdomen, and then aspirate the culture medium.

[0084] (4) Mix the culture medium containing feeder layer cells and HAT culture medium evenly, add 100 μL to each well of a 96-well cell culture plate, and place in a 37°C cell culture incubator.

[0085] 4. Preparation of Splenocytes

[0086] (1) Before cell fusion, eye blood was collected from superimmunized mice in a 1.5 mL centrifuge tube and placed in a 37°C incubator for 2 h. The tube was then centrifuged at 4000 rpm for 6 min and the supernatant was collected as a positive control and stored in a -20°C refrigerator.

[0087] (2) After blood was drawn from the eyeball, the mouse was killed by dislocating the neck, and then immersed in 75% alcohol for 5 minutes. The mouse was then fixed on a foam board with its abdomen facing upward.

[0088] (3) Transfer the mouse to the clean bench, use sterile scissors and forceps to cut open the mouse's abdominal epidermis, use new scissors to cut open the mouse's peritoneum, find the mouse's spleen, and then use another set of sterile scissors and forceps to remove the spleen.

[0089] (4) Place the spleen on a 200-mesh nylon mesh and slowly grind it with scissors. While grinding, continuously add GNK solution to keep the spleen cells moist. The spleen cells flow through the nylon mesh into the small beaker below.

[0090] (5) After grinding, transfer the solution in the small beaker to a 50 mL centrifuge tube, rinse the small beaker with GNK solution, and add it to the centrifuge tube. Centrifuge at 1000 rpm for 10 min, discard the supernatant, gently flick the cell clumps at the bottom of the centrifuge tube with your fingers, add 20 mL of GNK solution to resuspend the cells, and place in a 37°C cell culture incubator for later use.

[0091] 5. Cell Fusion

[0092] (1) Treatment of SP / 20 cells: Pour away the old culture medium, add new 1640 complete culture medium, resuspend the cells, transfer to a 50 mL centrifuge tube, centrifuge at 1000 rpm for 10 min, discard the supernatant, add 20 mL of GNK solution, and resuspend the cells.

[0093] (2) Use a cell counting plate to count spleen cells and SP / 20 cells respectively. Take 10 μL of cell suspension and mix it with 90 μL of trypan blue staining solution. Mix them in a ratio of 8:1 between spleen cells and SP / 20 cells. Centrifuge the mixed cell suspension at 1000 rpm for 10 min. Pour off the supernatant, gently flick off the cell pellet, and place the centrifuge tube in a 37°C warm water environment.

[0094] (3) Pipette 1 mL of preheated PEG 1500 and slowly add it dropwise using a pipette while continuously rotating the centrifuge tube. Add the solution within 90 seconds and then let it stand for 90 seconds.

[0095] (4) GNK was then added to terminate the reaction. 1 mL was added dropwise every 30 s, 3 mL was added dropwise every 30 s, and 11 mL was added dropwise every 30 s. After standing for 5 min, 25 mL of GNK was added. During this time, a 37 °C water bath was replaced in time to maintain the temperature.

[0096] (5) Centrifuge at 1000 rpm for 10 min, discard the supernatant, gently flick the cells, add HAT medium to resuspend and mix, add 100 μL per well to the culture plate with feeder cells, and culture in a 37°C cell culture incubator.

[0097] 6. Screening of Hybridoma Cell Positive Wells

[0098] Five days after cell fusion, cell clusters can be observed under the microscope. At this time, half of the cell culture plates are replaced with medium, 100 μL of medium in the wells is removed, and 100 μL of new HAT medium is added. Two days after half of the medium is replaced, positive hybridoma cell wells are screened by indirect ELISA. pH108R recombinant protein and pET-32a vector-expressed protein are used as coating sources, cell supernatant is used as primary antibody, and mouse eye blood (1:1000 dilution) is used as positive control. Select cell wells that react well with pH108R recombinant protein and do not react with pET-32a vector-expressed protein. Replenish the fluid for the positive wells screened out initially and recheck two days later.

[0099] 7. Subcloning of positive hybridoma cells

[0100] After retesting, subclone the positive hybridoma cell wells using the limiting dilution method. The specific steps are as follows:

[0101] (1) For the first subcloning, feeder cells need to be prepared. Mix the feeder cells with HT medium and plate 100 μL per well in a 96-well cell culture plate.

[0102] (2) Discard the old culture medium in the positive cell wells, add 200 μL of new HT culture medium, and gently blow the bottom of the plate to resuspend the cells.

[0103] (3) Pipette 10 μL of the cell suspension and mix it with an equal amount of 0.04% trypan blue staining solution, pipette and mix evenly, and pipette 10 μL onto a cell counting plate. Observe and count the number of living cells under a fluorescent inverted microscope.

[0104] (4) Based on the number of 1.5 cells per well, calculate the total number of cells required for the entire 96-well cell culture plate. Based on the count, dilute the cells with HT culture medium and add 100 μL per well to the culture plate with feeder cells and culture in a 37°C cell culture incubator.

[0105] (5) One week after subcloning, the wells with cell clusters were identified by indirect ELISA to screen positive cell lines. After three subclonings, hybridoma cell lines that stably secreted anti-pH108R protein monoclonal antibodies were screened.

[0106] 8. Western Blot Verification of Positive Hybridoma Cells

[0107] Western Blot was used to identify the reaction between the supernatant of positive hybridoma cell lines and pH108R protein. pH108R protein was used as the detection source, pET-32a carrier protein was used as the control, the supernatant of positive hybridoma cell lines was used as the primary antibody, and Goat Anti-Mouse IgG / HRP (1:5000) was used as the secondary antibody. Western Blot results are shown in Figure 5 , all 7 hybridoma cell lines showed obvious coloration in lane 1, but no coloration in lane 2, indicating that these hybridoma cell lines can recognize the linear epitope of pH108R protein.

[0108] 9. IFA Verification of Positive Hybridoma Cells

[0109] The eukaryotic expression system was used to transiently transfect the pcDNA3.1-pH108R plasmid to express the eukaryotic pH108R protein, and the reaction between the pH108R protein expressed by the eukaryotic system and the supernatant of the positive hybridoma cell line was identified by indirect immunofluorescence test. The specific process of immunofluorescence test is as follows:

[0110] First, spread 293T cells to 70%, and transfect 293T cells with pcDNA3.1-pH108R plasmid according to the instructions of the manual, and culture them in a 37°C cell culture incubator for 48 hours. Use 4% paraformaldehyde to fix the cells for 30 minutes and block with 5% skim milk for 2 hours; add cell supernatant containing 0.3% TritonX-100 as the primary antibody, immune mouse serum as the positive control, and non-immune mouse serum as the negative control, and incubate the cells at 37°C for 1 hour. After washing with PBST 5 times, add 100μL Goat Anti-Mouse IgG / Cy3 (1:200) to each well and place it in the dark at 37°C for 1 hour; after staining with DAPI, use a fluorescence microscope to image the cells, blue fluorescence is the nucleus, and red fluorescence is the pH108R protein of ASFV. IFA verifies the reactivity of hybridoma cell lines with eukaryotic expressed proteins. See details for details. Figure 6 .

[0111] 10. Expansion and cryopreservation of hybridoma cells

[0112] (1) Expansion culture: After the cells in the positive wells have filled the bottom of the plate, they are expanded to 24-well plates for culture. If the cells have filled 3 to 4 24-well plates, they are transferred to T25 plates for continued culture.

[0113] (2) Cell freezing: If the cell density in T25 grows to about 80% and the cells are growing well, the cells can be frozen: Pour out the old culture medium in the bottle, add 5 mL of new 1640 complete culture medium, gently blow the side wall to resuspend the cells, and transfer the cell suspension to a 10 mL centrifuge tube. Centrifuge at 1000 rpm for 10 minutes, pour out the supernatant, and flick the cell clumps at the bottom. Add 1 mL of serum-free freezing solution, blow and mix, and transfer to a cryopreservation tube. Mark the relevant information on the cryopreservation tube, put it in a -80°C refrigerator, and transfer it to a liquid nitrogen tank for long-term storage the next day.

[0114] Example 3

[0115] Identification of Antigen Epitopes Recognized by Monoclonal Antibodies

[0116] 1. Construction of truncated fragment expression vector

[0117] The primers of pH108R truncated protein were designed using SnapGene software, and the pH108R protein gene sequence was used as a template, and the truncated fragment gene sequence was amplified by PCR using the primers in Table 6. The PCR product was recovered, and the pET-32a plasmid and the truncated fragment were double-digested with restriction endonucleases (BamH I and Xho I), connected using T4 DNALigase, and transformed into DH5α competent cells. The bacterial solution identified as positive by bacterial solution PCR was sent for sequencing and sequence comparison.

[0118] Table 6 Primer sequence list

[0119]

[0120]

[0121] 2. Expression and identification of truncated proteins

[0122] The strain with the correct sequencing alignment was expanded and the plasmid was extracted and transformed into BL21 (DE3) competent cells. The successfully constructed truncated protein recombinant expression bacteria were expanded and cultured, and the inducer was added at 1:1000, and the protein was induced to express in a shaking incubator at 16°C overnight. After the induction, the bacterial solution was centrifuged, the bacterial precipitate was resuspended with PBS, and ultrasonically broken in an ice-water mixture until the bacterial solution became clear and transparent. The supernatant precipitate was separated by centrifugation at 12000rpm at 4°C, and the supernatant was identified by SDS-PAGE and Western Blot ( Figure 7 ).

[0123] 3. Identification of epitope regions recognized by monoclonal antibodies

[0124] Indirect ELISA identification

[0125] Indirect ELISA was used to identify the epitope regions recognized by the supernatants of 7 hybridoma cells. The supernatant of truncated protein ultrasonic fragmentation was used as the coating source, the protein expressed by the pET-32a vector was used as the negative control, the cell supernatant was used as the primary antibody, and GoatAnti-MouseIgG / HRP (1:5000) was used as the secondary antibody.

[0126] Dot-Blot Identification

[0127] (1) Cut the NC membrane into strips of appropriate size and use a punch to gently press and punch holes.

[0128] (2) Soak the NC membrane in ddw and allow it to dry naturally.

[0129] (3) Use a pipette to spot the truncated protein ultrasonic supernatant, pH108R protein (positive control), and vector-expressed protein (negative control) into each round hole, 1.5 μL each time. After drying, spot again. Repeat the operation three times.

[0130] (4) After the membrane is dried, it is placed in a 5% skim milk solution and blocked at 37°C for 2 h.

[0131] (5) Pour off the blocking solution and wash the membrane with PBST solution for 15 min. Mark the NC membrane, place it in the corresponding cell supernatant, and incubate at 37°C for 1 h.

[0132] (6) Wash the membrane with PBST solution for 15 min, add Goat Anti-Mouse IgG / HRP (1:5000), and incubate at 37°C for 1 h.

[0133] (7) The NC membrane was washed in PBST solution for 20 min, developed using an ECL chemiluminescence kit, and photographed for analysis.

[0134] The results of the identification of the monoclonal antibody with the first truncated protein and the second truncated protein are shown in Figure 8 and Fig. 9 .

[0135] 4. Large-scale preparation and purification of monoclonal antibodies

[0136] The monoclonal antibody is prepared in large quantities by in vivo induction method. The specific steps are as follows:

[0137] (1) One week in advance, 500 μL of incomplete Freund's adjuvant was injected intraperitoneally into parous BALB / c mice.

[0138] (2) Observe the status of hybridoma cells. If the cells are in good condition and the density reaches about 80%, resuspend the cells and centrifuge at 1000 rpm for 10 min.

[0139] (3) Discard the supernatant, flick off the cell clumps, resuspend the cells in an appropriate amount of serum-free 1640 medium, count the cells, and inject 1×10 6 cells.

[0140] (4) After cell injection, the abdomen of the mouse gradually expands. During this period, the physical and mental state of the mouse should be observed in a timely manner. If the mouse's abdomen is obviously swollen, its movements are slow, and its mental state is poor, the mouse should be killed by cervical dislocation and the ascites collected.

[0141] (5) Centrifuge the ascites at 6000 rpm for 15 min, and aspirate the supernatant with a pipette, trying to avoid aspirating the white fat on the top layer and the blood cells at the bottom. After aliquoting, store in a -80℃ refrigerator.

[0142] Protein A affinity chromatography column was used to purify ascites. The specific steps are as follows:

[0143] (1) Equilibration: Equilibrate the column with binding buffer.

[0144] (2) Sample loading: Dilute the ascites 5-fold with binding buffer, filter with a 0.22 μm filter head, and add it to the Protein A affinity chromatography column. Control the flow rate to maintain at 1 mL / min and repeat the column loading three times.

[0145] (3) Washing: Use binding buffer to wash away unbound proteins until the protein indicator no longer turns blue.

[0146] (4) Elution: Elute the protein with elution buffer. Add 100 μL of neutralizing solution to the centrifuge tube where the protein is collected in advance to adjust the pH so that the pH of the eluate mixed with the neutralizing solution is in the range of 7.2 to 7.4. Use a protein indicator to detect until the solution no longer turns blue and then stop eluting.

[0147] (5) Dialysis: Boil the dialysis bag with deionized water for 10 min, place the purified monoclonal antibody into the dialysis bag, and dialyze it in PBS overnight. Use NanoDrop 2000 to measure the concentration of the monoclonal antibody, mark it, and store it in a -80℃ refrigerator after aliquoting.

[0148] (6) Use SDS-PAGE to identify the purity of the monoclonal antibody. Fig.10 .

[0149] The titer of monoclonal antibodies was determined by indirect ELISA. Fig.11 , the titer of 1D1 is 1:2.56×10 5 , 4C6 titer is 1:5.12×10 5 The results of monoclonal antibody affinity determination are shown in Fig.12 , the affinity constant of 1D1 is 3.70×10 8L / moL, the affinity constant of 4C6 is 1.03×10 8 L / moL.

[0150] 5. Polyclonal antibody variable region genes and sequences

[0151] The amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody of the present invention are shown in SEQ ID No. 2 and SEQ ID No. 3, respectively, and the nucleic acid sequences thereof are shown in SEQ ID No. 4 and SEQ ID No. 5, respectively.

[0152] SEQ ID No.2:

[0153] LRRR*PWSLGPSSHCILYSNRPQSPHLSDC*GPCRQCWWM*LQSVWP*P*TSGCR*YYYFQDRLRQSIPDPVQASVLSSASSRW*SCSQKPCRTSSLKPQALPAQSLTAAAGP

[0154] SEQ ID No.3:

[0155] Q*RWGY*ST*SCLLGCWC*CSGFPLPAVML**PKLHSPCLSVLEIKPPSLADLVRALDTLMETPIYIGTCRRQASLQSS*STKFPTDFLGSQTGSVAVDQRQISHSRSAEWRLMIWEFMSALKVHMFPSRSVLGPSWS*NGLMLHQLYPSSHHPVSLGELT

[0156] SEQ ID No.4:

[0157] TTGAGGAGACGGTGACCGTGGTCCCTTGGCCCCAGTAGTCATCATTGTATCTTGTACAGTAATAGACCGCAGAGTCCTCATTTGTCAGACTGCTGAGGACCATGTAGGCAGTGCTGGTGGATGTGACTGCAGTCAGTTTGGCCTTGACCTTGAACTTCTGGTTGTAGGTAGTACTACTATTTCCAGGATAGATTGCGCCAATCCATTCCAGACCCTGTCCAGGCCTCTGTTTTATCCAGTGCATCCAGTAGGTGGTAAAGCTGTAGCCAGAAGCCTTGCAGGACATCTTCACTGAAGCCCCAGGCCTTGCCAGCACAGTCCCTGACTGCTGCAGCTGGACCTA

[0158] SEQ ID No.5:

[0159] CAATAAAGGTGGGGGTACTAGTCGACATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCCGCTTCCAGCAGTGATGCTGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGGACACATTGATGGAAACACCTATTTACATTGGTACCTGCAGAAGGCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGTGGCAGTGGATCAGCGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGATGATCTGGGAGTTTATGTCTGCTCTCAAAGTACATATGTTCCCCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTAAGCTTGGGAGAACTAACA

[0160] 6. Synthesis and coupling of polypeptide

[0161] After two truncation and identification of the epitope region by indirect ELISA and Dot-Blot, the B cell epitope region of pH108R protein was preliminarily determined to be 40 SNIHIPYQWLA 50 The amino acid sequence was synthesized into a polypeptide named P1, which had 11 amino acids in total. The synthesized polypeptide was coupled with bovine serum albumin (BSA) using the glutaraldehyde method, and the synthesized product was packaged and stored in a -80°C ultra-low temperature refrigerator.

[0162] 7. Identification of Peptides

[0163] The coupled polypeptide was used as the coating source, and the reactivity of the coupled polypeptide with ASFV-positive pig serum and the screened ASFVpH108R monoclonal antibody and ASFV-positive pig serum was determined by Peptide-ELISA and Dot-Blot method. Fig.13 and Fig.14 As shown, polypeptide P1 can react with ASFV positive pig serum and ASFVpH108R monoclonal antibody. Therefore, the B cell epitope sequence recognized by the monoclonal antibody screened in this study is shown in SEQ ID No.1.

[0164] SEQ ID No.1: SNIHIPYQWLA

[0165] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. An antigenic epitope of the pH108R protein of African swine fever virus, characterized in that: The antigen epitope is located at positions 40 to 50 of the pH108R protein of the African swine fever virus, and the amino acid sequence of the antigen epitope is shown in SEQ ID No.

1.

2. Use of an antigenic epitope of the pH108R protein of African swine fever virus in the preparation of a monoclonal antibody against the pH108R protein of African swine fever virus, characterized in that: The antigenic epitope is as shown in claim 1.

3. A monoclonal antibody against African swine fever virus pH108R protein, characterized in that: The monoclonal antibody can specifically bind to the antigen epitope described in claim 1.

4. The monoclonal antibody against pH108R protein of African swine fever virus according to claim 1, characterized in that: The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID No.2, and the amino acid sequence of the light chain variable region of the monoclonal antibody is shown in SEQ ID No.

3.

5. A nucleic acid encoding a monoclonal antibody against the pH108R protein of African swine fever virus, characterized in that: The nucleic acid encoding the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No.4, and the nucleic acid encoding the light chain variable region of the monoclonal antibody is shown as SEQ ID No.

5.

6. An expression vector, characterized in that: The expression vector comprises the nucleic acid of claim 5.

7. A host cell, characterized in that The host cell comprises the expression vector according to claim 6.

8. A kit for detecting African swine fever virus pH108R protein, characterized in that: The kit comprises the monoclonal antibody according to claim 3 and / or the nucleic acid according to claim 5 and / or the expression vector according to claim 6 and / or the host cell according to claim 7.

9. Use of the monoclonal antibody according to claim 3 and / or the nucleic acid according to claim 5 and / or the expression vector according to claim 6 and / or the host cell according to claim 7 in the preparation of a drug for inhibiting and / or neutralizing the pH108R protein of African swine fever virus.

Citation Information

Patent Citations

  • Physarum polycephalum 14-3-3 protein monoclonal antibodies and preparation method thereof

    CN103627676A

  • Anti-African swine fever virus p30 protein monoclonal antibody, preparation method and B cell epitope screening and identification

    CN113512095A

  • Antigen epitope peptide of African swine fever virus pD205R protein, monoclonal antibody and application of antigen epitope peptide and monoclonal antibody

    CN117659134A

  • General monoclonal antibody for african swine fever virus strains as well as preparation method therefor and application thereof

    WO2016086554A1

Cited By

  • Monoclonal antibody BY017 combined with African swine fever virus P30 protein and application thereof

    CN120484103A